Abstract:
The present invention relates to new medicaments, pharmaceutical compositions and methods of treatment of cancer. Disclosed are trimetallic clusters for use as a medicament, in particular in the treatment of cancer including metastasis. Preferably, the compounds are provided in the form of pharmaceutically acceptable salts. Preferred compound include trinuclear ruthenium- arene clusters as exemplified by the compounds 1a and 1b shown in Figure 1.
Abstract:
The present invention provides new complexes and medicaments based on dinuclear ruthenium complexes comprising bridging thiolato or selenolato ligands. The complexes comprise a Ru 2 X 3 or a Ru 2 X 2 core, in which each one of said X is independently selected from said bridging ligands, with the proviso that at least one ligand comprises a substituted or unsubstituted phenyl moiety.
Abstract translation:本发明提供了基于双核钌络合物的新的配合物和药物,其包含桥连硫醇或硒酸酯配体。 络合物包含Ru 2 X 3或Ru 2 X 2核,其中所述X中的每一个独立地选自所述桥连配体,条件是至少一个配体包含取代或未取代的苯基部分。
Abstract:
The present invention relates to new medicaments, pharmaceutical compositions and methods of treatment of cancer. Disclosed are trimetallic clusters for use as a medicament, in particular in the treatment of cancer including metastasis. Preferably, the compounds are provided in the form of pharmaceutically acceptable salts. Preferred compound include trinuclear ruthenium- arene clusters as exemplified by the compounds 1a and 1b shown in Figure 1.
Abstract:
The present invention relates to novel organometallic compounds for use as a medicine, in particular in photodynamic therapy against various diseases, such as cancer or inflammatoryand/or immune disorders. The compounds comprise a central porphyrin or phtalocyanine backbone to which ligandlinkers coordinated to at least one transition metal are attached. Eta-5 or eta-6 arenes further bind to the transition metal. According to a preferred embodiment, the compound is a tetranuclear Ruthenium (+II) complex.
Abstract:
The present invention relates to organometallic compounds useful in the treatment of metastasis. The organometallic compounds comprise a ligand that is convalently bound to a bioactive compound, which is an inhibitor of a resistance pathway or a derivative thereof. Preferably, the organometallic compounds are half-sandwich ("piano-stool") compounds. The compounds of the present invention offer a high variability with respect to the bioactive compound and to the nature of the ligand bound to a central transition metal.
Abstract:
Novel chemical compounds of the general formula K + A - , in which K + is a 5- or 6- membered heterocyclic ring having 1-3 hetereo atoms, which can be independently N, S, or 0; with the proviso that at least one of the hetereo atoms must be a quaternized nitrogen atom having a -R'CN substituent, wherein R' is alkyl (C 1 to C 12 ); the heterocyclic ring having up to 4 or 5 substituents independently chosen from the moieties: (i) H; (ii) halogen or (iii) alkyl (C 1 to C 12 ) , which is unsubstituted or partially or fully substituted by further groups, preferably F, Cl, N(C n F( 2n+1-x )H x ) 2 , O(C n F (2n+1-x) H x ), S0 2 (C n F( 2n+1-x) H x ) 2 or C n F (2n+1-x )H x where 1 n F (2n+1-x.) H x .) 2 , O(C n F (2n+1-x) H x ), S0 2 (C n F (2n+1-x )H x ) 2 or C n F( 2n+1-x )H x where 1 - is any anion that provides a salt with a low melting point, below about 100 °C; A - can be halide, BF 4 - , PF 6 - , N0 3 - , CH 3 CO 2 - , CF 3 SO 3 - , (CF 3 SO 2 ) 2 N - , (CF 3 SO 2 ) 3 C - CF 3 CO 2 - or N(CN) 2 - or [BF 3 RCN] - . These compounds can be used as industrial solvents, especially as ligands for efficient catalyst recycling.
Abstract:
A new procedure for constructing cryogenic storage tanks involves erecting a freestanding metal liner. The liner is sized and configured to withstand the hydraulic forces the concrete wall of the tank being poured without the need for temporary stiffeners on the inside surface of lower portions of the liner. Lateral tension ties can be connected to anchor ties on an outward surface of the liner and used to tie the liner to outer formwork. These ties may be spaced up to about 2 m apart. Studs can also be provided on the outer surface of the liner, and a cylindrical ring of cryogenic steel can be integrated into the liner.
Abstract:
The present invention relates to a method of producing hydrogen gas and carbon dioxide in a catalytic reaction from formic acid, said reaction being conducted in an aqueous solution over a wide temperature range and already at room temperature (25°C). The reaction is advantageous because it can be tuned to take place at very high rates, up to about 90 litre H2 / minute / litre reactor volume. The gas produced is free of carbon monoxide. The method of the present invention is particularly suitable for providing hydrogen for a motor, fuel cell or chemical synthesis.